Welcome!

News Feed Item

ATL1102 for Stem Cell Mobilisation Trial Commencement

TOORAK, Australia, March 17, 2014 /PRNewswire/ -- Antisense Therapeutics (ASX:ANP) is pleased to advise that it has commenced dosing in its Phase I Stem Cell Mobilisation (SCM) Human Proof of Concept trial of ATL1102, the Company's second generation antisense drug targeting the VLA-4 receptor. The trial will assess the safety, tolerability and effect of ATL1102 on the release of hematopoietic stem cells (CD34+) into the blood when dosed alone and in combination with an existing therapy (Granulocyte Colony Stimulating Factor (G-CSF)). The randomised, open label study of ATL1102 dosed over 5 days (given on day 1, 3 and 5) in 10 healthy volunteers is being conducted by leading Clinical Research Organisation, Nucleus Network at its clinical trial unit at the Alfred Hospital, Melbourne, Victoria. (The Study "Protocol Synopsis" following this announcement provides further information).

With the necessary screening, dosing and follow up of patients, ANP anticipates that results from the trial will be reported mid 2014.

The mobilisation (release) of these stem cells from the bone marrow into the blood is part of an important medical procedure used to improve outcomes for patients undergoing chemotherapy to treat certain cancers. The stem cells released into the blood are then collected and stored before high dose chemotherapy and then re-infused to replace those lost during chemotherapy in order to re-establish the immune system. The basis for using ATL1102 in the SCM indication is related to the role of VLA-4 in regulating the release of CD34+ stem cells from the bone marrow, with another drug that also targets VLA-4 having been shown to increase CD34+ stem cell release in humans. In a previous study in Multiple Sclerosis patients, ATL1102 demonstrated similar activity to that drug by increasing CD34+ levels in the blood.

Dr Jason Lickliter, Medical Director of Nucleus Network and Principal Investigator for the trial said "This human Phase I trial of ATL1102 is designed to evaluate whether ATL1102 can improve mobilization of CD34+ stem cells when used in combination with standard mobilisation therapy to levels that would make it clinically beneficial for use in the collection of stem cells for transplantation. There is an acknowledged clinical need for increasing mobilisation levels beyond those achieved by the current therapeutic approach, and so I am very pleased to be working with Antisense Therapeutics to assess the merits of ATL1102 in this important clinical setting."

Antisense Therapeutics Limited CEO and Managing Director Mark Diamond said "The stem cell mobilisation opportunity for ATL1102 while commercially attractive with, by our estimation, a market potential of several hundred million dollars per annum, also presents as an excellent return on investment proposition given costs are expected to be relatively low for developing the drug in this  indication. We believe that positive outcomes from this trial will strongly enhance our drug's potential for this application and naturally we relish the opportunity to further develop a drug that can potentially provide better outcomes for cancer patients. We look forward to successfully conducting the study and to reporting results from this SCM trial which are anticipated mid-year."

Protocol Synopsis


Title

A Phase I, Randomised, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ATL1102 Alone and in Combination with G-CSF in Healthy Volunteers

Study Number

1102SCM-CT01

Study Design

Single-centre, open-label, randomised, parallel group study

Objectives

  • To assess the safety and tolerability of subcutaneous doses of ATL1102 alone, and in combination with G-CSF in healthy volunteers
  • To assess the pharmacodynamics of ATL1102 alone, and in combination with G-CSF in healthy volunteers
  • To assess the pharmacokinetics of ATL1102 alone, and in combination with G-CSF in healthy volunteers

Endpoints

  • Safety and tolerability of ATL1102 in combination with G-CSF
  • Pharmacokinetic profiles of ATL1102
  • Pharmacodynamic measures including release of CD34+ haematopoietic stem cells and progenitor cells

Number of patients

It is planned that 10 patients will be randomised to one of 3 dosing groups for the study.

Key Patient Criteria

Healthy male volunteers between the ages of 18 and 50 years of age.  BMI between 19 and 32 kg/m2

Dosing

ATL1102 and G-CSF will be delivered as subcutaneous (s.c.) injections according to the following schedule:

  • Group A (n = 3) will receive Granulocyte-Colony Stimulating Factor (G-CSF; 10µg/kg/day) via s.c. administration on days 1, 2, 3, 4 and 5
  • Group B (n = 3) will receive ATL1102 (400 mg/day) via via s.c. administration on days 1, 3 and 5
  • Group C (n = 4) will receive G-CSF (10µg/kg/day) on days 1, 2, 3, 4 and 5 and ATL1102 (400 mg/day) on days 1, 3 and 5.

Per Patient Duration

Up to 28 days screening, one week dosing, one week follow up

Trial Location

Nucleus Network, Melbourne, VIC.

Principal Investigator

Dr Jason Lickiter

Trial Standard

GCP

 

About Stem Cell Mobilisation in Cancer treatment: stem cell mobilization and transplantation is a medical procedure used to improve clinical outcomes for patients undergoing chemotherapy to treat cancer.  Some chemotherapy has toxic effects on bone marrow, so hematopoietic stem cells are collected from the blood of the patient – or from a donor's blood – before the patient receives chemotherapy. These collected stem cells are then stored and given back later to replace those lost during chemotherapy (engraftment). There are normally only a small number of stem cells in the blood, so stem cell mobilization agents are used to increase this number before stem cell collection from a donor or more typically from a patient. Granulocyte colony-stimulating factor (G-CSF) is the main agent used for hematopoietic stem cell mobilization. While G-CSF is successful in mobilizing hematopoietic stem cells, there is often the need for additional complimentary mobilizing therapies. The major product used in combination with G-CSF is Mozobil® however there is an opportunity to improve on the level of stem cell release achieved with G-CSF alone or in combination with Mozobil.  At least 2 million CD34+ cells per kg are required for durable reconstitution of the immune system, however greater than 5 million CD34+ cells per kg, sourced in one or more collections, lead to improved engraftment and patient outcomes.

ATL1102 is a second generation antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4). In inflammation, white blood cells (leukocytes) move out of the bloodstream into the inflamed tissue, for example, the Central Nervous System (CNS) in MS, and the lung airways in asthma. The inhibition of VLA-4 may prevent white blood cells from entering sites of inflammation, thereby slowing progression of the disease. VLA-4 is a clinically validated target in the treatment of MS. Antisense inhibition of VLA-4 has demonstrated positive effects in a number of animal models of inflammatory disease including MS with the MS animal data having been published in a peer reviewed scientific journal.  ATL1102 was previously shown by Antisense Therapeutics to be highly effective in reducing MS lesions in a Phase IIa clinical trial in MS patients.  The company has also lodged an International patent application on ATL1102 based on preliminary data in mice and humans supporting its' potential application as a stem cell mobilization agent for use in combination with G-CSF to improve the level of stem cell release achieved with G-CSF alone.

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals  Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with multiple  sclerosis (MS), ATL1103 a second-generation antisense drug designed to block GHr production and thereby lower blood  IGF-I levels and is in clinical development as a potential treatment for growth and other GH-IGF-I disorders, ATL1102  (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.

Contact Information:
Website: www.antisense.com.au 
Managing Director: Mark Diamond +61 (3) 9827 8999
USA Investor/Media: Joshua Drumm +(1) 212 375 2664; [email protected] 
Australia Investor/Media: Simon Watkin +61 (0)413 153 272; [email protected] 

 

SOURCE Antisense Therapeutics Limited

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
Updating DevOps to the latest production data slows down your development cycle. Probably it is due to slow, inefficient conventional storage and associated copy data management practices. In his session at @DevOpsSummit at 20th Cloud Expo, Dhiraj Sehgal, in Product and Solution at Tintri, will talk about DevOps and cloud-focused storage to update hundreds of child VMs (different flavors) with updates from a master VM in minutes, saving hours or even days in each development cycle. He will also...
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
"There's a growing demand from users for things to be faster. When you think about all the transactions or interactions users will have with your product and everything that is between those transactions and interactions - what drives us at Catchpoint Systems is the idea to measure that and to analyze it," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York Ci...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
A look across the tech landscape at the disruptive technologies that are increasing in prominence and speculate as to which will be most impactful for communications – namely, AI and Cloud Computing. In his session at 20th Cloud Expo, Curtis Peterson, VP of Operations at RingCentral, will highlight the current challenges of these transformative technologies and share strategies for preparing your organization for these changes. This “view from the top” will outline the latest trends and developm...
Discover top technologies and tools all under one roof at April 24–28, 2017, at the Westin San Diego in San Diego, CA. Explore the Mobile Dev + Test and IoT Dev + Test Expo and enjoy all of these unique opportunities: The latest solutions, technologies, and tools in mobile or IoT software development and testing. Meet one-on-one with representatives from some of today's most innovative organizations
SYS-CON Events announced today that Dataloop.IO, an innovator in cloud IT-monitoring whose products help organizations save time and money, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Dataloop.IO is an emerging software company on the cutting edge of major IT-infrastructure trends including cloud computing and microservices. The company, founded in the UK but now based in San Fran...
SYS-CON Events announced today that Linux Academy, the foremost online Linux and cloud training platform and community, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Linux Academy was founded on the belief that providing high-quality, in-depth training should be available at an affordable price. Industry leaders in quality training, provided services, and student certification passes, its goal is to c...
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in Embedded and IoT solutions, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 7-9, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/Big Data, HPC and E...
IoT is at the core or many Digital Transformation initiatives with the goal of re-inventing a company's business model. We all agree that collecting relevant IoT data will result in massive amounts of data needing to be stored. However, with the rapid development of IoT devices and ongoing business model transformation, we are not able to predict the volume and growth of IoT data. And with the lack of IoT history, traditional methods of IT and infrastructure planning based on the past do not app...
The unique combination of Amazon Web Services and Cloud Raxak, a Gartner Cool Vendor in IT Automation, provides a seamless and cost-effective way of securely moving on-premise IT workloads to Amazon Web Services. Any enterprise can now leverage the cloud, manage risk, and maintain continuous security compliance. Forrester's analysis shows that enterprises need automated security to lower security risk and decrease IT operational costs. Through the seamless integration into Amazon Web Services, ...
Due of the rise of Hadoop, many enterprises are now deploying their first small clusters of 10 to 20 servers. At this small scale, the complexity of operating the cluster looks and feels like general data center servers. It is not until the clusters scale, as they inevitably do, when the pain caused by the exponential complexity becomes apparent. We've seen this problem occur time and time again. In his session at Big Data Expo, Greg Bruno, Vice President of Engineering and co-founder of StackIQ...